Accreditation for Pharmacists
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity provides 1 hour (0.1 CEU) of continuing pharmacy education credit (activity # 0204-000-13-473-L01P).
This activity is provided free of charge. Participants must participate in the entire presentation, submit an enrollment code (announced during the webinar), and complete the course evaluation to receive continuing pharmacy education (CPE) credit. Participants will process CPE credit online at http://elearning.ashp.org/my-activities, with the option of printing a CPE certificate. CPE credit will be reported directly to CPE Monitor. View full CE processing instructions.
Methods and Format
This is a live web-based activity consisting of audio, presentation slides, and an activity evaluation tool. A live webinar brings the presentation to you. Listen to the speaker present in “real time” as you watch the slides on the screen. You will have the opportunity to ask the speaker questions at the end of the program. Please join the conference at least 5 minutes before the scheduled start time for important announcements.
This continuing pharmacy education activity was planned to meet the needs of pharmacists in all practice settings, especially those who are interested in bleeding disorders, hemostasis, emergency medicine, critical care, emerging therapies, patient safety, and formulary management.
Managing an acute bleed in a patient with a bleeding disorder is a dynamic, ongoing process that requires frequent dosage adjustment and monitoring. Decisions about how to treat such a patient need to be made quickly and require continuous clinical and laboratory assessment of hemostatic parameters, including clotting factor levels. This activity will use clinical case scenarios to demonstrate innovative strategies for managing bleeds using various pharmacologic approaches.
Time for questions and answers from the webinar audience will be provided at the end of the presentation.
At the conclusion of this application-based educational activity, participants should be able to
- Outline a plan for assessing a patient with bleeding and concern for a bleeding disorder.
- Outline a plan for managing bleeding in an acutely-ill patient with a bleeding disorder.
- Employ a strategy involving formulary and systems decisions, including the use of concentrated clotting factor products that avoids treatment delays.
- Illustrate selected situations, such as development of inhibitors, requiring a change in therapy.
William E. Dager, Pharm.D., BCPS (AQ-Cardiology)
UC Davis Medical Center
William E. Dager, Pharm.D., BCPS (AQ-Cardiology), is a pharmacist specialist at UC Davis Medical Center in Sacramento, California, where he is responsible for managing challenging cases in anticoagulation, pharmacokinetics, and critical care. He also is clinically active with the cardiology service and serves as the director of the postgraduate year two (PGY-2) residency in cardiology at UC Davis. In addition, Dr. Dager holds three academic positions. He is Clinical Professor of Pharmacy at the University of California, San Francisco (UCSF) School of Pharmacy and Clinical Professor of Medicine at the University of California, Davis (UC Davis) School of Medicine. He also serves as Clinical Professor at Touro School of Pharmacy in Vallejo, California.
Dr. Dager earned his Doctor of Pharmacy degree at UCSF and completed a residency at UC Davis Medical Center in Sacramento. In addition, he completed the University of Pittsburgh Nephrology Pharmaceutical Care Preceptorship. He is a board-certified pharmacotherapy specialist and fellow of the American College of Clinical Pharmacy (ACCP), American Society of Health-System Pharmacists (ASHP), California Society of Hospital Pharmacists, and Society of Critical Care Medicine (SCCM).
Dr. Dager's research interests focus on anticoagulation, critical care medicine, cardiovascular disease, and pharmacokinetics and pharmacodynamics. He has authored numerous articles, book chapters, and scientific reviews, and he coauthored "Anticoagulation Therapy: A Point-of-care Guide" published by ASHP in 2011. He also regularly makes presentations at national and international educational conferences.
Dr. Dager serves as a reviewer and editorial board member for several medical journals, and he currently is chair of the Editorial Advisory Board Panel on Anticoagulation for The Annals of Pharmacotherapy. He has served as a site coordinator for the ASHP Research and Education Foundation Antithrombotic Pharmacotherapy Traineeship.
Dr. Dager has received multiple teaching and professional awards, including the 2008 ACCP Best Practice Award.
Mark T. Reding, M.D.
Center for Bleeding and Clotting Disorders
University of Minnesota Medical Center, Fairview
University of Minnesota Medical School
Mark T. Reding, M.D., is Director of the Center for Bleeding and Clotting Disorders at University of Minnesota Medical Center in Minneapolis. In this role he is responsible for providing and coordinating patient care in the clinic and hospital for all adult patients followed by the Center, which is a hemophilia treatment center supported by the Centers for Disease Control and Prevention. Dr. Reding also serves as Medical Director of the Inpatient Hematology/Oncology Unit at University of Minnesota Medical Center. In addition, he is Associate Professor of Medicine in the Division of Hematology, Oncology, and Transplantation at the University of Minnesota.
Dr. Reding received his Bachelor of Science degree in Microbiology and Biology at South Dakota State University in Brookings. He then earned a Doctor of Medicine degree at University of Minnesota Medical School in Minneapolis. He is board certified in hematology.
Dr. Reding’s clinical interest is the treatment of non-malignant hematologic disorders with particular emphasis on disorders of hemostasis and thrombosis, including hemophilia. His current research efforts focus on the immune response to factor VIII, the cellular mechanisms involved in the synthesis of factor VIII inhibitors, and the immunologic consequences of gene therapy. He has also served as the local principal investigator for multi-center clinical trials. His research has been published in peer-reviewed journals.
Dr. Reding considers teaching to be the most important and rewarding aspect of his career, and he twice was awarded the Outstanding Clinical Mentor Award from his division at the Medical School. In addition to teaching responsibilities at the University, he frequently speaks at educational programs for physicians and other health care professionals.
Dr. Reding is a member of American Society of Hematology, Hemostasis and Thrombosis Research Society (HTRS), and International Society for Thrombosis and Hemostasis. He recently completed a two-year term on the board of directors for HTRS.
Viewing the Webinar as a Group
To arrange for colleagues to participate in this webinar as a group, one person serving as the group coordinator should register for the webinar. The group coordinator will receive an e-mail confirmation with instructions for joining the webinar. A few minutes before the webinar begins, the group coordinator should launch the webinar link. Once the webinar has been activated, the coordinator will have the option to open the audio via VoIP (Voice Over IP) on the webinar toolbar or use a touch tone phone with the provided dial-in information. At the conclusion of the activity, the group coordinator will complete a brief online evaluation and report the number of participants at that site. Each participant will process their own continuing education statements online.
Webinar System Requirements
Be sure to view the webinar system requirements for Windows, Mac, iOS, and Android prior to the activity.